title: Roxithromycin versus amoxicillin-clavulanic acid in the treatment of respiratory tract infections.
abstract: A multicenter, double-blind, double-dummy trial was conducted in 96 general practice patients with upper and lower respiratory tract infection to compare the efficacy and tolerance of roxithromycin (150 mg b.i.d.) and amoxicillin-clavulanic acid (500 mg/125 mg t.i.d.). Good clinical response was obtained in 96% and 95% of cases, respectively, but only 4% of patients receiving roxithromycin volunteered adverse events possibly or probably related to their test treatment, as opposed to 17% of those receiving amoxicillin-clavulanic acid. The results indicate that both drugs are equally effective in the treatment of respiratory tract infection, but that roxithromycin is better tolerated.
authors.affiliation: Kortessem Laboratory, Brussels, Belgium.
authors.forename: D
authors.initials: D
authors.lastname: Lousbergh
authors.forename: G
authors.initials: G
authors.lastname: Jochems
authors.forename: L
authors.initials: L
authors.lastname: Everaert
authors.forename: M
authors.initials: M
authors.lastname: Puttemans
mesh_terms: D000328:Adult; D000658:Amoxicillin / Q000009:adverse effects / Q000627:therapeutic use*; D019980:Amoxicillin-Potassium Clavulanate Combination; D002969:Clavulanic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000627:therapeutic use; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D015575:Roxithromycin / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D002969:Clavulanic Acids; D015575:Roxithromycin; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin